PA8563901A1 - Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico - Google Patents

Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico

Info

Publication number
PA8563901A1
PA8563901A1 PA20038563901A PA8563901A PA8563901A1 PA 8563901 A1 PA8563901 A1 PA 8563901A1 PA 20038563901 A PA20038563901 A PA 20038563901A PA 8563901 A PA8563901 A PA 8563901A PA 8563901 A1 PA8563901 A1 PA 8563901A1
Authority
PA
Panama
Prior art keywords
phenyl
antranilico
esteres
replaced
hydroxamate
Prior art date
Application number
PA20038563901A
Other languages
English (en)
Inventor
Stephen Douglas Barrett
Michael David Kaufman
Gordon William Rewcastle
Julie Ann Spicer
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PA8563901A1 publication Critical patent/PA8563901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A ESTERES OXIGENADOS DE DERIVADOS DE ACIDO (4-FENIL-SUSTITUIDO) AMINO-BENZOHIDROXAMICO, A COMPOSICIONES FARMACEUTICAS Y A METODOS PARA USARLOS.
PA20038563901A 2002-01-23 2003-01-23 Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico PA8563901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35110602P 2002-01-23 2002-01-23

Publications (1)

Publication Number Publication Date
PA8563901A1 true PA8563901A1 (es) 2003-09-05

Family

ID=27613459

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038563901A PA8563901A1 (es) 2002-01-23 2003-01-23 Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico

Country Status (14)

Country Link
US (1) US6770778B2 (es)
EP (1) EP1467965A1 (es)
JP (1) JP2005515251A (es)
AR (1) AR038212A1 (es)
BR (1) BR0307071A (es)
CA (1) CA2472367A1 (es)
DO (1) DOP2003000556A (es)
HN (1) HN2003000038A (es)
MX (1) MXPA04005528A (es)
PA (1) PA8563901A1 (es)
PE (1) PE20030925A1 (es)
TW (1) TW200302084A (es)
UY (1) UY27618A1 (es)
WO (1) WO2003062189A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101013932B1 (ko) 2003-10-21 2011-02-14 워너-램버트 캄파니 엘엘씨 Ｎ-[(ｒ)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
EP1699477A2 (en) * 2003-12-11 2006-09-13 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
TW200619206A (en) * 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
CN109053523B (zh) 2005-10-07 2022-03-25 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
CA2671982C (en) 2006-12-14 2016-01-26 Exelixis, Inc. Methods of using mek inhibitors
CA2706241C (en) * 2007-10-05 2015-12-22 Sanofi-Aventis Deutschland Gmbh Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
US8993630B2 (en) 2008-11-10 2015-03-31 Bayer Intellectual Property Gmbh Substituted sulphonamido phenoxybenzamides
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
CN102656142A (zh) 2009-10-21 2012-09-05 拜耳制药股份公司 取代的苯磺酰胺
EP2491016A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
CA2777071A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
CA2789696C (en) 2010-02-25 2017-11-07 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US20130059851A1 (en) 2010-03-09 2013-03-07 Dana-Farber Cancer Institute, Inc. Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy
CN103282351A (zh) 2010-10-29 2013-09-04 拜耳知识产权有限责任公司 取代的苯氧基吡啶
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
BR112014029338A2 (pt) 2012-05-31 2017-06-27 Bayer Pharma AG biomarcadores para determinação da resposta eficaz dos tratamentos de pacientes com carcinoma hepatocelular (hcc)
EA030613B1 (ru) 2012-10-12 2018-08-31 Экселиксис, Инк. Новый способ получения соединений для применения при лечении рака
JP2016034900A (ja) * 2012-11-26 2016-03-17 中外製薬株式会社 ５−置換−２−フェニルアミノ−ベンズアミド類の製造方法
CN103508965B (zh) * 2013-09-27 2015-04-08 天津大学 一种二苯西平类衍生物的合成方法
CN105646438A (zh) * 2015-12-22 2016-06-08 天津大学 一种缩酮类糖醇基小分子凝胶因子及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2082171A (en) * 1933-05-24 1937-06-01 Winthrop Chem Co Inc Basically substituted amino acridine derivatives
NL62219C (es) * 1945-05-07
US2553914A (en) * 1948-03-22 1951-05-22 Ward Blenkinsop & Co Ltd Substituted diphenylamine 2-monocarboxylic acids and the production thereof
US3781358A (en) * 1968-05-29 1973-12-25 E Anderson Intermediates for preparing acridines
CH541608A (de) 1970-11-06 1973-09-15 Ciba Geigy Ag Verfahren zur Herstellung von Nitrodiphenylaminen und deren Verwendung
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
DE3608726A1 (de) * 1986-03-15 1987-09-17 Hoechst Ag Verwendung aminosubstituierter benzoesaeuren als heilmittel gegen diarrhoe und arzneimittel auf basis dieser verbindungen
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US5068250A (en) * 1988-09-29 1991-11-26 Trustees Of University Of Pennsylvania Irreversible ligands for nonsteroidal antiinflammatory drug and prostaglandin binding sites
AU4090093A (en) 1992-05-29 1993-12-30 Yamanouchi Pharmaceutical Co., Ltd. Medicine containing benzoic acid derivative and novel benzoic acid derivative
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
AU6858996A (en) 1995-08-28 1997-03-19 Interlab Corporation Pharmaceutical compositions for the treatment of infectious diseases
IL118657A0 (en) 1996-06-14 1996-10-16 Arad Dorit Inhibitors for picornavirus proteases
AU5610398A (en) 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
IL132840A (en) 1997-07-01 2004-12-15 Warner Lambert Co Derivatives 4 - bromo or 4 - benzohydroxamic acid iodine amino iodine and pharmaceutical preparations containing them for use as MEK inhibitors
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
ES2274572T3 (es) * 1997-07-01 2007-05-16 Warner-Lambert Company Llc Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek.
ATE239000T1 (de) 1997-10-28 2003-05-15 Warner Lambert Co 7-substituierte chinazolin-2,4-dionen verwendbar als antibakterielle mittel
EP1140062B1 (en) * 1999-01-07 2005-04-06 Warner-Lambert Company LLC Treatment of asthma with mek inhibitors
CA2349180A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett Anthranilic acid derivatives
JP3811775B2 (ja) 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル

Also Published As

Publication number Publication date
EP1467965A1 (en) 2004-10-20
MXPA04005528A (es) 2005-03-23
UY27618A1 (es) 2003-08-29
AR038212A1 (es) 2005-01-05
BR0307071A (pt) 2004-12-28
JP2005515251A (ja) 2005-05-26
TW200302084A (en) 2003-08-01
PE20030925A1 (es) 2003-10-29
WO2003062189A1 (en) 2003-07-31
US6770778B2 (en) 2004-08-03
US20030232889A1 (en) 2003-12-18
CA2472367A1 (en) 2003-07-31
HN2003000038A (es) 2003-01-21
DOP2003000556A (es) 2003-10-31

Similar Documents

Publication Publication Date Title
PA8563901A1 (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
PA8563801A1 (es) Esteres hidroxamato del acido n-(4-fenil sustituido)- antranilico
NO20044744L (no) Karbaminsyreforbindelser omfattende et piperazinledd som HDASinbibitorer
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
EE200100485A (et) Uudsed ühendid ja kompositsioonid proteaasi inhibiitoritena
EA200501570A1 (ru) Новые гидроксаматы как лечебные средства
CY1111170T1 (el) Ενωσεις διαρυλ αιθερα ουριας
MY144659A (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
NO20090175L (no) Stabile laquinimod sammensetninger
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
ATE440833T1 (de) Antithrombotische diamide
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
NO20083836L (no) N-hydroksyakrylamidforbindelser
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
MX2008010884A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1.
AU2003291867A1 (en) Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
CY1111574T1 (el) Παραγωγα βουτανοϊκου οξεος, διαδικασιες για την παρασκευη τους, φαρμακευτικες συνθεσεις που τα περιλαμβανουν και θεραπευτικες εφαρμογες αυτων
MY148393A (en) Malate salts, and polymorphs of (3s, 5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
ATE253359T1 (de) Antithrombotische mittel
BR0311306A (pt) Derivados de amida como inibidores da atividade enzimática de renina
IL169496A0 (en) Imino acid derivatives for use as inhibitors of matrix metalloproteinases
DE69828522D1 (de) Antithrombotische mittel
CY1107277T1 (el) Βενζισοξαζολες